Breaking Finance News

A statement released earlier today by Raymond James Financial Inc. about Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) bumps the target price to $16.00

Boasting a price of $7.19, Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) traded 4.17% higher on the day. With the last stock price close down -11.62% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Adaptimmune Therapeutics PLC – ADR has recorded a 50-day average of $7.18 and a two hundred day average of $8.47. Volume of trade was up over the average, with 333,449 shares of ADAP changing hands over the typical 124,945

Raymond James Financial Inc. bumped up the target of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) to $16.00 stating a potential upside of 1.23%.

On Tuesday March 29, 2016, Leerink Swann released a statement for Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) bumped down the target price from $24.00 to $23.00 that suggested an upside of 1.98%.

Performance Chart

Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP)

With a total market value of $0, Adaptimmune Therapeutics PLC – ADR has with a one year low of $6.19 and a one year high of $14.78 .

Brief Synopsis About Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company's TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.